Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: The question is still ongoing

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages

  Giovannetti, Elisa ^a,b   Tibaldi, Carmelo ^c   Falcone, Alfredo ^b,c   Danesi, Romano ^b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

^c Department of Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTIDINE DEAMINASE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MERCAPTOPURINE; NAVELBINE; OXALIPLATIN; SORAFENIB; TRASTUZUMAB; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ENZYME DEFICIENCY; ETHNICITY; GENE FREQUENCY; GENOTYPE; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; BLOOD; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; NEOPLASM; NOTE; PATIENT SELECTION; PHENOTYPE; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CYTIDINE DEAMINASE; DEOXYCYTIDINE; GENOTYPE; HUMANS; NEOPLASMS; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 77952505307     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.4928     Document Type: Letter

References (10)

1. Ciccolini J, Dahan L, André N, et al: Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabinebased chemotherapies. J Clin Oncol 28:160-165, 2010
2. Eliopoulos N, Cournoyer D, Momparler RL: Drug resistance to 5-aza-2′- deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42:373-378, 1998 (Pubitemid 28430367)
3. Wong A, Soo RA, Yong WP, et al: Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 41:77-88, 2009
4. Tibaldi C, Giovannetti E, Vasile E, et al: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797-1803, 2008
5. Sugiyama E, Kaniwa N, Kim SR, et al: Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32-42, 2007 (Pubitemid 350003048)
6. Bergman AM, Pinedo HM, Jongsma APM, et al: Decreased resistance to gemcitabine (2′,2′-Difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57:397-406, 1999 (Pubitemid 29065288)
7. Maitland ML, Vasisht K, Ratain MJ: TPMT, UGT1A1 and DPYD: Genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 27:432-437, 2006
8. Veltkamp SA, Beijnen JH, Schellens JH: Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy. Oncologist 13:261-276, 2008 (Pubitemid 351679901)
9. Tibaldi C, Giovannetti E, Tiseo M, et al: Correlation between cytidine deaminase genotype and clinical outcome/toxicity in advanced non-small cell lung cancer patients treated with gemcitabine/platinum-based chemotherapy. e-Poster: PD10.3.1, 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009. www.2009worldlungcancer.org
10. Crinò L, Ludovini V, Pistoia L, et al: Polymorphisms of genes involved in Platinum/Gemcitabine-based metabolism correlate with clinical response and toxicity in patients with advanced non-small cell lung cancer. e-Poster: PD7.4.3, 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009. www.2009worldlungcancer.org